Concepedia

Karl Quint

KQ

Statistics

Publications

25

Citations

897

H-Index

16

Active since

2008

Affiliations

Philipps University of Marburg(Current)

Universitätsklinikum Erlangen

Paracelsus Medical University

Friedrich-Alexander-Universität Erlangen-Nürnberg

Salzburger Landeskliniken

Karl Quint is an author at Philipps University of Marburg specializing in medicine, oncology, and molecular oncology.

Publications per year

2008–2016

25

Publications

25

Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC

Karl Quint, Abbas Agaimy, Pietro Di Fazio et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2011 · 116 citations

, , +13

Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition

Karl Quint, Manuel Tonigold, Pietro Di Fazio et al. · International Journal of Oncology · 2012 · 81 citations · Full text

, , +17

Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines

Pietro Di Fazio, Roberta Montalbano, Daniel Neureiter et al. · Experimental Cell Research · 2012 · 74 citations

, , +5

Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer

Amir Avan, Karl Quint, Francesco Nicolini et al. · Current Pharmaceutical Design · 2012 · 63 citations

, , +16

The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis.

Pietro Di Fazio, Regine Schneider‐Stock, Daniel Neureiter et al. · PubMed · 2010 · 61 citations · Full text

, , +17

1–5 of 25